Document Type: Research article
Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran14176, Iran.
Islamic Azad University, Shahre Rey Branch.
School of chemistry, College of Science, University of Tehran, Tehran Iran.
Department of Toxicology and Pharmacology, Faculty of Pharmacy and Laboratory of Toxicology, Pharmaceutical Sciences Research Centre, Tehran University of Medical Sciences, Tehran 14155-6451, Iran.
Drug Design and development Research Center, Tehran University of Medical Sciences, Tehran, Iran.
The complex metabolic syndrome, diabetes mellitus, is a major human health concern in the world and is estimated to affect 300 million people by the year 2025. Several drugs such as sulfonylureas and biguanides are presently available to reduce hyperglycemia in diabetes mellitus. These drugs have side effects and thus searching for a new class of compounds is essential to overcome this problems.
A series of seven novel N-(4-phenylthiazol-2-yl)benzenesulfonamides derivatives were synthesized and assayed in-vivo to investigate their antidiabetic activities by streptozotocin-induced model in rat. These derivatives showed considerable biological efficacy when compared to glibenclamide, a potent and well-known antidiabetic agent, as a reference drug. Four of the compounds were effective, amongst which 13 show more prominent activity at 100 mg/Kg p.o. The experimental results are statistically significant at p < 0.05 level.